Why Is SYNDAX PHARMACEUTICA (SNDX) Stock Down Today?
By the Top Tier Newswire AI Desk · October 14, 2026 at 12:11 AM ET · reviewed against 17 wire stories
SYNDAX PHARMACEUTICA (SNDX) is down -15.71% in the latest session. Our newswire has captured 17 stories on SNDX across 9 sources in the last 36 hours, with AI sentiment reading bearish (avg 32/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Syndax Pharmaceuticals (SNDX) shares fell 15.71% to $13.95 as the company disclosed that its Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. The stock opened down more than 11% following the news that the annualized rate of forced vital capacity decline did not meet targets.
What Happened
Syndax announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint measuring annualized FVC decline. The company stated it will not pursue further development of axatilimab for IPF, though its chronic graft-versus-host disease program remains on track. The trial failure prompted a pending investigation notice from SueWallSt, which notified investors of the matter.
Analyst reactions have been mixed but generally supportive of the stock's current valuation. Stifel maintained its rating on the shares following the trial failure. H.C. Wainwright noted that the company's valuation remains unchanged after the miss, while Citi described the selloff as an attractive entry point. H.C. Wainwright reiterated a Buy rating with a $38 price target.
What The Data Shows
The stock has experienced a sharp decline over the last eight sessions, dropping 21.3% from $17.72 to $13.95. On October 13, 2026, the stock printed 14 fresh 52-week lows, while it had previously printed one fresh 52-week high. The 52-week range stands between $12.99 and $25.59. Syndax has a market capitalization of $1.5 billion and remains unprofitable with a trailing twelve-month EPS of -$2.51. Revenue grew 223.7% over the same period, but the net margin is -87.5%. The stock has a beta of 0.42. Sentiment has deteriorated, with the 30-day average at 41 out of 100 and the last seven days at 34 out of 100.
What To Watch
Investors will monitor the company's next scheduled earnings date and the broader coverage breadth as analysts adjust their models following the IPF trial miss.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 17 stories · 32/100 bearish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
7h agoPR NewswireBEARISH 34General
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of...
18h agoBarron'sBEARISH 22Earnings
Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans.
19h agoMarketChameleonBEARISH 34Earnings
Syndax drops after axatilimab misses MAXPIRe IPF endpoint, while cGVHD program stays on track
Syndax said the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of annualized rate of FVC decline and the company will not pursue further IPF development. Syndax emphasized axatilimab was well tolerated with a safety profile comparable to placebo and said the result does not affect ongoing axatilimab studies, including multiple trials in chronic GVHD with readouts expected later this year and in early 2028.
Stifel maintains Syndax stock rating after trial failure
Stifel maintains Syndax stock rating after trial failure
20h agoThe FlyBEARISH 42Analyst
Syndax valuation unchanged after trial miss, says H.C. Wainwright
20h agoThe FlyBULLISH 64Analyst
Syndax selloff brings attractive entry point, says Citi
21h agoInvesting.com MarketsBEARISH 38General
Why is Syndax Pharmaceuticals stock sliding today?
Why is Syndax Pharmaceuticals stock sliding today?
22h agoMarketChameleonBEARISH 34Earnings
Syndax halts axatilimab IPF plans after MAXPIRe misses FVC decline endpoint
October 13, 2026
Syndax said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint measuring annualized FVC decline, and the company does not plan further IPF development. The company emphasized axatilimab was well tolerated with no new safety signals and said the results do not affect ongoing cGVHD trials, with additional readouts expected later this year and in early 2028.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →